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Abstract Cancer metastasis is largely incurable and accounts for 90% of breast cancer
deaths, especially for the aggressive basal-like or triple negative breast cancer (TNBC).
Combining patient database analyses and functional studies, we examined the association of
integrin family members with clinical outcomes as well as their connection with previously
identified microRNA regulators of metastasis, such as miR-206 that inhibits stemness and
metastasis of TNBC. Here we report that the integrin receptor CD49b-encoding ITGA2, a direct
target of miR-206, promotes breast cancer stemness and metastasis. ITGA2 knockdown sup-
pressed self-renewal related mammosphere formation and pluripotency marker expression, in-
hibited cell cycling, compromised migration and invasion, and therefore decreased lung
metastasis of breast cancer. ITGA2 overexpression reversed miR-206-caused cell cycle arrest
in G1. RNA sequencing analyses revealed that ITGA2 knockdown inhibits genes related to cell
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cycle regulation and lipid metabolism, including CCND1 and ACLY as representative targets,
respectively. Knockdown of CCND1 or ACLY inhibits mammosphere formation of breast cancer
cells. Overexpression of CCND1 rescues the phenotype of ITGA2 knockdown-induced cell cycle
arrest. ACLY-encoded ATP citrate lyase is essential to maintain cellular acetyl-CoA levels.
CCND1 knockdown further mimics ITGA2 knockdown in abolishing lung colonization of breast
cancer cells. We identified that the low levels of miR-206 as well as high expression levels
of ITGA2, ACLY and CCND1 are associated with an unfavorable relapse-free survival of the pa-
tients with estrogen receptor-negative or high grade breast cancer, especially basal-like or
TNBC, possibly serving as potential biomarkers of cancer stemness and therapeutic targets
of breast cancer metastasis.
Copyright ª 2020, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Metastasis causes a majority of cancer related deaths,
estimated 9.6 million globally in 2018.1 Breast cancer is the
most common cancer in women other than skin cancer and
its five-year survival rate decreases to 27% when distant
metastases develop.2,3 Among all breast cancers, one of
the most aggressive subtypes with early metastases is triple
negative breast cancer (TNBC) which largely overlaps with
basal-like breast cancer, and has most limited options for
targeted therapy so is associated with a poor prognosis.4
Therefore, it is imperative to identify metastasis drivers
and novel targets of TNBC.
Over the last two decades, human tumor cells with
enriched stem cell properties (stemness) have been iden-
tified to initiate tumor growth, and demonstrated to
accelerate progression with key attributes of resistance to
therapies and evasion to immune attacks.5e12 Nevertheless,
comparing to its importance in primary tumor growth,
cancer stemness might be more indispensable for metas-
tasis initiation,13,14 including clustered circulating tumor
cells mediated polyclonal metastasis.15,16 Genetic and
epigenetic aberrations are known to enable tumor plas-
ticity and stemness.9,17e19 However, targeting of cancer
stemness and metastasis has yet to be widely achieved due
to the lack of comprehensive understanding of potentially
heterogeneous stemness drivers and modulators. In this
study we focus on identifying and linking metastasis-driving
stemness factors and pathways to targetable surface re-
ceptors. We report here a new pathway coupling integrin
CD49b to its upstream and downstream regulation
mechanisms.
Integrins include a large family of over twenty subunit
molecules forming ab heterodimers with binding affinity for
various extracellular membrane components. Many integrins
are key players in physiological and pathological processes.20
However, the intrinsic roles and signaling pathways of many
integrins in breast cancer metastasis are not fully eluci-
dated. Our previous studies have demonstrated that micro-
RNAs (miRs) regulate breast cancer chemoresistance and
progression in TNBC.21e24 Specifically, miR-206 suppresses
breast cancer stemness and lung metastasis.21 Microarray-
based global transcriptome analyses revealed that ITGA2,
which encodes a surface integrin receptor CD49b (integrin
a2), is one of the genes suppressed by miR-206. Further
clinical correlation studies identified that ITGA2 expression
is one of the few integrin alpha genes associated with un-
favorable of relapse-free survival (RFS) of basal-like breast
cancer patients. CD49b is relatively known to be expressed
in immune cells especially in regulatory T cells (Treg).25
However, its tumor-intrinsic role and regulatory signaling in
breast cancer progression are largely elusive.
To test the hypothesis that CD49b is stemness driver for
metastasis of breast cancer, we utilized multiple TNBC
model systems in vitro and in vivo to assess the functional
importance of CD49b (ITGA2), and to identify its signaling
pathways and targets. In this study, we found that CD49b
enhances breast cancer stemness and metastasis, requiring
the genes involved in lipid metabolism and cell cycle
pathways, such as ACLY and CCND1, respectively.
Materials and methods
Animal studies
All mice used in this study were kept in specific pathogen-
free facilities in the Animal Resources Center at North-
western University and Case Western Reserve University. All
animal procedures complied with the NIH Guidelines for the
Care and Use of Laboratory Animals and were approved by
the respective Institutional Animal Care and Use Commit-
tees. Animals were randomized by age and weight. The
exclusion criterion of mice from experiments was sickness
or conditions unrelated to tumors. Sample sizes were
determined based on the results of preliminary experi-
ments. NSG and NOD-Scid mice were used for tail vein in-
jection experiments with MDA-MB-231 cells and 4T1 cells
expressing luciferase2-fused eGFP (pFU-L2G) or tdTomato
(pFU-L2T).14 For spontaneous metastasis experiments the
murine mouse cell lines (4T1) were injected in the mam-
mary fat pad of BALB/c mice. Imaging of all in vivo ex-
periments was performed using a Perkin Elmer IVIS.
Human databases and cell line expression analyses
Relapse free survival plots were obtained from KM-Plot
(www.Kmplot.com/analysis).26 This tool downloads gene
expression data, relapse free and overall survival informa-
tion from GEO (Affymetrix microarrays only), EGA and TCGA.
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It uses a PostgreSQL server, which integrates gene expres-
sion and clinical data simultaneously. KM-Plot analyzes the
prognostic value of a particular gene by splitting the patient
samples into two groups according to various quantile ex-
pressions of the proposed biomarker and the best cut off was
chosen for each analysis. The hazard ratio with 95% confi-
dence intervals and logrank p values were calculated.
Breast Cancer Miner was used for the analyses of any
event free survival of basal like and/or TNBC (IHC-based)
patients. This tool uses GSE studies as well others indepen-
dent of KM plot.27,28 The total number of patients analyzed
was 876 (filtered from 5861). For the RNA sequencing-based
gene expression correlation analyses, the updated number
of patients with basal-like and/or TNBC was 276.
UCSF Xena browser was used to study the ITGA2 gene
expression through different breast cancer cell lines ac-
cording to their subtype.29 The profiles of the set of breast
cancer cell lines are seen in the study by Heiser 2012.30 The
single cell RNA sequencing data of human circulating tumor
cells isolated from breast cancer patients and xenografts
were retrieved from the published databases GSE109761
and GSE11106516,31 and compared using Wilcox t test.
RNA sequencing and data analysis
Total RNA extraction was performed using Trizol and phase
separation by chloroform, then extraction by alcohol.
Samples were submitted to the RNA core for deep
sequencing analysis. RNA sequencing was performed on a
HiSeq 4000 at Northwestern University’s Center for Genetic
Medicine Sequencing core facility and a library was made
using TruSeq Total RNA-Seq Library Prep. The raw data files
were submitted to the GEO repository (GSE132961) of the
NCBI tracking system (scheduled release on Feb 01, 2020).
Sequencing data was aligned using STAR32 and analyzed
using HTSeq33 and DESeq2.34 Differentially expressed genes
were subject to a cutoff of FDR <0.05 and Log2 (Fold
Change) > 0.48 or < 0.48. Pathway analysis was per-
formed on significantly-differentially expressed genes in
Metascape (http://metascape.org).35
Cell culture
MDA-MB-231 and BT20 cells were cultured in DMEM high
glucose, supplemented with 10% FBS and 1% Pen/step
antibiotic. 4T1 cells were cultured in RPMI media supple-
mented with 10% FBS and 1% Pen/strep antibiotic. MDA-MB-
231 cells were obtained from ATCC, and BT20 and 4T1 cells
were originally from ATCC and expanded by Dr. Dai Hori-
uchi. Transcriptome and phenotypic analyses of these cells
matched the published profiles.
Cell transfections
Transient transfection of breast cancer cells with Dharmacon
small interfering RNAs (siRNAs), or microRNA mimics was
performed once or in tandem using Dharmafect transfection
reagents (siRNA control:D-001810-01-05, ITGA2siRNA: L-
004566-00-0005, CCND1: L-003210-00-0020; set of 4 ITGA2
siRNA: LU-004566-00-0005; miR control: CN-001000-01-05).
Cells were at least 70% confluent at the moment of
transfection, siRNA concentration is 100 nM per transfection.
Most phenotypic analyses were conducted 2 days after the
last transfection. Mammosphere formation in vitro and
metastasis assays in vivo were done on the following day
after the second transfection. For rescue experiments, cells
were co-transfected with GFP empty vector or GFP ITGA2
cDNA in addition to either miR control or miR-206; alterna-
tively OFP vector control, OFP-CCND1 cDNA vector in addi-
tion to either siRNA control or siITGA2 (Sino Biological,
CV025, CV026, HG13024-ACG, HG10905-ACR). Transfection
of vectors were made in serum free media, using PolyJet
(Signa Gen Laboratories, SL100688).
Mammosphere assay
Cells were plated at a low density of 1000 cells in suspen-
sion in a 6- well plate covered with poly-HEMA in PRIME-
XV Tumorsphere serum-free medium (Irvine scientific,
91130). 8 days after plating a total number of spheres
(diameter >50 mm) were counted for each well and pictures
were taken.
Scratch wound assays of cell migration and invasion
Plates were coated with collagen type I (Corning 354231) and
incubated at RT for at least an hour prior to cell plating. Cells
were plated in an image lock 96 well plate overnight at a
confluency of 20K cells per well. On next day morning a
scratch was created using the IncuCyte wound maker. After
washing of the floating cells, the remaining adherent cells
were monitored for migratory filling of the wound by Incu-
cyte. For thecell invasion assay, thewashedwells of adherent
cells with the scratch wound was covered with another layer
of growth factor-reduced Matrigel for 1 h at 37 C or room
temperature. Then the plate was washed again and added
with culture medium. The filling of the scratch wound was
monitored real-time by IncuCyte over 24e48 h.
Cell cycle analysis
Cells were collected, then fixed with 70% alcohol, washed
with PBS, incubated with RNAse A for 1 h then propidium
iodide dye was added. Some cells were stained with DAPI
and the RNAse A incubation was skipped. Cells were kept in
the dark and at 4C until flow cytometry analysis on LSRII
(PE and UV channels).
3’UTR luciferase assay
Vectors expressing luciferase with the 3’UTR region of
ITGA2 as well as luciferase assay reagents were obtained
through Active Motif and their protocol was followed
(Switchgear, Lightswitch luciferase assay kit, 32031; GAPDH
control, 32014; ITGA2 3’utr: pLS_3UTR).
Flow cytometry
Cells were detached using 2 mM EDTA in PBS and cell surface
expression of CD49b was measured (Biolegend 359310).
Annexin V staining was performed using FITC Annexin V
apoptosis detection Kit (BD Biosciences 556547).
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Western blotting
Cells were lysed by RIPA buffer supplemented with Amresco
protease inhibitor cocktail (1:100 diluted) and centrifuged
for 10 min at 4C and 10,000 RPM. Protein concentration
was measured through a Bradford assay and 20-40ug of
protein were loaded for each sample. Antibodies used:
Cd49b (Rabbit pAb, Thermo Fisher Scientific PA5-26061),
pFAK, total FAK (Rabbit, Cell Signaling, mAb 8556 and pAB
3285), b-actin (Mouse mAb, Abcam ab8224). Secondary
antibodies where HRP conjugated (Promega, Rabbit W401B,
Mouse W402B) for ECL detection using Pierce ECL2 solution
(Thermo Fisher Scientific, 1896433A).
Immunohistochemistry
Tissue was first deparaffinized by xylene incubation fol-
lowed by rehydration of tissue obtained through alcohol
incubation in decreasing concentrations. Heat induced an-
tigen retrieval was obtained using a decloaking chamber in
decloaking solution for 20 min (Biocare Medical, RD913L).
Further staining of primary antibody was performed
following Dako envision plus kit and DAB staining (Anti-
ITGA2, Sigma HPA063556). Hematoxolin and eosin staining
was performed following dehydration of the tissue by in-
cubation with increasing concentrations of alcohol. Tissues
were later mounted with permount.
Acetyl-CoA measurement
Samples were fixed then stored at 80C freezer, then dried
with N2 blowing. MeOH:water mix with an internal standard
(2C13 Ace-CoA) in each sample. Samples were diluted with
buffer before SPE onwater HLB plate. Sample was elutedwith
MeOH. The LC/MS analysis was performed on AB Sciex Qtrap
5500 coupled to Agilent UPLC/HPLC system. All samples are
analyzed by Agilent proshell 120 SB-C18 column 100 Å, 2.7 mm,
2.1 mm  100 mm coupled to an Agilent UPLC/HPLC system,
which was operated at a flow rate of 450 uL/min.
Statistical analysis
Student’s t-test was performed for most of the comparisons
except for the ones specified such as in human database
analyses. Probabilities under 0.05 were considered signifi-
cant and represented with one star (*). Probabilities under
0.01 and 0.001 were represented with two stars (**) and
three stars (***), respectively.
Results
Identification of ITGA2 as an oncogenic promotor of
breast cancer metastasis
To identify potential phenotype drivers of breast cancer
progression and metastasis, we first analyzed the associ-
ation of all integrin encoding genes with clinical outcomes
using Breast Cancer Miner with multiple GSE databases
containing 2997 unique breast cancer samples.26 We
found that high expression levels of eight integrin genes
correlated with unfavorable RFS of basal-like breast
cancer, including ITGA2, ITGA5, ITGA6, ITGA7, ITGAV,
ITGB1, ITGB3, and ITGB6, whereas the rest of 17 integrin
genes were associated with favorable outcomes (Fig. S1),
implicating heterogeneous functions and relevance of
integrin genes in breast cancer.
In order to narrow down the candidate screening of
integrin regulators in TNBC stemness and metastasis, we
examined possible association of these integrins with sub-
types of breast cancer cell lines and known stemness reg-
ulators of breast cancer, such as microRNAs we have
identified in previous studies.21 Based on the gene expres-
sion profiles of over 50 established breast cancer cell lines,
high ITGA2 expression levels are mainly observed in basal A
subtype cells (Fig. S2). Our previous work revealed that
miR-206 suppresses TNBC stemness and metastasis.21 Based
on our microarray dataset GEO-GSE 59751, we found that
the expression of CD49b-encoding ITGA2 was specifically
inhibited by miR-206 whereas other integrin genes such as
ITGB1 levels remained unaffected (Fig. S3a). Consistently,
we observed that the miR-206 over-expressing breast can-
cer cells caused minimal, residual lung metastases along
with reduced CD49b levels, compared to the significant lung
metastases mediated by control cells upon tail vein infusion
(Fig. S3b). Therefore, we hypothesized that ITGA2 pro-
motes cancer stemness and metastasis in TNBC as an
oncogenic target of miR-206.
To examine the importance of ITGA2 in TNBC metastasis,
we set out to determine if ITGA2 knockdown (KD) mimics
miR-206 overexpression in regulating breast cancer metas-
tasis in vivo. Upon tail vein injection, MDA-MB-231 cells with
reduced CD49b levels due to ITGA2-KD had significantly
decreased lung colonization in NOD/SCID mice (Fig. 1AeC).
While equivalent cells of the control and ITGA2-KD groups
homed to the lungs immediately after tail vein injection,
cells with ITGA2-KD had a reduced capacity to colonize the
lungs as measured from 24 h to 4 days post injection.
In addition, the murine 4T1 TNBC cells were utilized to
investigate the effects of Itga2 KD on spontaneous metas-
tasis in immune-competent Balb/c mice. When these cells
were orthotopically transplanted at large numbers
(106 cells per injection), 4T1 cells could metastasize from
the mammary fat pads to the lungs within a week.36 Using
IVIS imaging of luciferase-labeled cells, we found that
silencing Itga2 gene with reduced Cd49b expression only
modestly compromised primary tumor growth, as measured
by BLI (Fig. 1DeF), without a significant reduction on tumor
weight (Fig. S3c, t-test P Z 0.17, n Z 7). However, Itga2
silencing dramatically suppressed lung metastasis after
normalization on tumor weight (Fig. 1G). Reduced Cd49b
levels in engrafted tumors and inhibited lung metastases of
Itga2-KD 4T1 cells were validated by immunohistochemistry
and H & E staining (Fig. S3d and Fig. 1H). In contrast to the
lungs, metastasis of 4T1 to the liver and other organs was
not detected in these mice within the short observation
window (data not shown).
ITGA2 is a target of miR-206 enhancing
mammosphere formation and cancer stemness
The inhibitory effects of miR-206 on ITGA2 mRNA and
CD49b protein expression (both cellular and surface protein
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levels) were further validated in MDA-MB-231 cells upon
transient transfection of miR-206 mimics, measured by
qRT-PCR, immunoblotting, and flow cytometry analyses
(Fig. 2AeC and S3a). To determine if ITGA2 is a direct
target of miR-206, we utilized multiple algorithms including








Figure 1 ITGA2 knockdown inhibits lung colonization and metastasis. (A-C) Bioluminescence images (a), CD49b flow analyses (b),
and normalized lung colonization signals (c, ratio of the total flux compared to D0) of NOD/Scid mice on day 0 (D0), 1 (D1), and 4
(D4) post tail vein infusion of L2T/L2G-labeled MDA-MB-231 cells, control and ITGA2-KD. n Z 4, *PZ 0.02 (D1) and **P Z 0.004 (D4)
for paired comparisons (t-test). Error bars represent S.D. values. (D) Bioluminescence images of tumor growth signals of mouse 4T1
cells, the control and Itga2 KD, on day 1 (D1), 3 (D3), 5 (D5), and 9 (D9) post orthotopic implantation into the 4th mammary fat pads
of BALB/c mice. (E) Flow analyses of mouse Cd49b levels in 4T1 cells  Itga2-KD prior to implantation. (F) 4T1 tumor growth
analyses (tumor burden) (total flux p/s, n Z 7, *t-test P< 0.01). Error bars represent S.D. values. (G) Bioluminescence images (top
panels) and normalized lung metastasis by primary tumor burden (total flux/tumor weight) of the mouse lungs bearing 4T1
spontaneous metastases on D9, n Z 7, t-test P Z 0.05. Error bars represent S.D. values. (H) H & E staining images of 4T1 breast
tumors and spontaneous lung metastases (present in the control group and absent in the Itga2 KD group) on day 9 post orthotopic
implantations shown in d. Scale bars Z 20 mm.











Figure 2 ITGA2 is a target of miR-206 and promotes mammosphere formation and stemness factor expression. (AeB) ITGA2 mRNA
(top panel) and protein (bottom panel) levels are reduced by transfected miR-206 in MDA-MB-231 cells, measured by qRT-PCR and
immunoblotting, respectively. ***t-test P < 0.001. Error bars represent S.D. values. (C) CD49b surface protein expression inhibited by
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identified a predicted miR-206 binding site within its 3’UTR
region (Fig. 2D). The ITGA2 3’UTR region (2 kb) was then
cloned downstream of a luciferase reporter gene in
pLS_3UTR. The luciferase reporter expression/activity was
inhibited by co-transfected miR-206 and the inhibition was
reversed when the three nucleotides were mutated from C
to T (U) within the predicted site for miR-206 binding
(Fig. 2D and E). These data suggest that ITGA2 is inhibited
by miR-206 through a direct binding to its 3’UTR site.
We continued to examine the importance of ITGA2 in
regulating cancer stemness. First, using the online Breast
Cancer Gene Expression Miner v4.0, we observed a positive
correlation between expression of IGTA2 and the breast
cancer stem cell marker CD44 in human basal-like and
TNBC, measured by RNA sequencing (Fig. S4A). We also
detected a higher ITGA2 mRNA expression and protein
levels in CD44þ versus CD44- tumor cells isolated from TNBC
PDXs (Fig. S4B). Notably, siITGA2-mediated knockdown (KD)
did not alter CD44 protein levels (Fig. S4C), suggesting a
possible independent role of ITGA2 in TNBC. Mimicking the
mammosphere-inhibitory phenotype of miR-206 as we
previously observed,21 ITGA2 KD suppressed mammosphere
formation of MDA-MB-231 cancer cells (Fig. 2F and G). The
effectiveness of ITGA2 knockdown in MDA-MB-231 cells was
confirmed by both immunoblotting and flow analyses
(Fig. 2H and I). Furthermore, we investigated the effects of
miR-206 upregulation and ITGA2 KD on pluripotency tran-
scription factors and focal adhesion kinase (FAK) signaling.
FAK is known to be activated by many integrins37 and the
FAK signaling pathway promotes stemness in breast cancer
cells.38 Indeed, both ITGA2 KD and miR-206 upregulation
similarly decreased the protein levels of pluripotency
marker OCT 3/4, and inhibited the phosphorylation/acti-
vation of FAK, without altering the total FAK protein levels
(Fig. 2J). To determine the importance of CD49b in
tumorigenicity in vivo, we sorted CD49high (þþ) and
CD49 low/- cells from the control and ITGA2 KD cells,
respectively. ITGA2 KD significantly inhibited the tumor
growth and tumorigenesis from 100-1000 cells upon ortho-
topic implantation into the mammary fat pads of NSG mice
(tumor weight 0 for 33% implantations of CD49b negative
cells) (Fig. 2K and L and S4d). ITGA2 KD further inhibited
mRNA levels of SOX2, measured by RT-PCR (Fig. S4e). These
results demonstrate that ITGA2/CD49b is intrinsically
required to enhance cancer stemness in TNBC.
ITGA2 knockdown reduces cell cycle progression
We further investigated whether CD49b regulates cancer
stemness by modulating cell cycle or cellular viability.
Similar to the miR-206-induced effects, ITGA2 KD
reduced confluence (Fig. 3A and S4f) and counts of MDA-
MB-231 breast cancer cells (Fig. 3B). We then examined
if alterations in cell cycle and cell death contribute to
the phenotypic changes. Mimicking the effects of miR-
206 upregulation, ITGA2 KD in MDA-MB-231 cells
increased the percentage of cells in the G1 phase and
decreased populations in cycling phases such as G2/M
(Fig. 3C and D). As expected, exogenous cDNA-mediated
overexpression of CD49b rescued the cell cycle arrest
caused by miR-206 in MDA-MB-231 cells a (Fig. 3E).
Consistently, in a different TNBC line BT-20, ITGA2 KD
also resulted in an accumulation of G1 arrested cells
(Fig. 3E and S4g-h).
We then measured cell death in breast cancer cells upon
altering CD49b expression. From the cell cycle analyses,
ITGA2 KD did not cause significant changes of subG1 phase
(Fig. 3CeE), and differences in levels of cell death were not
detectable in either Annexin V or propidium iodide (PI)-
stained cells (Fig. S5a-b). A DNA binding dye with red
fluorescence only marked a marginal increase of cytotox-
icity (from 2% to 5%) of ITGA2 KD cells during cell migration
in a scratch wound healing assay (Fig. S5c-d). Furthermore,
in order to ensure minimal off-target effects of siRNAs, we
employed four individual ITGA2 siRNAs #1e4 for additional
validation studies. Most of the siITGA2s had minimal or
marginal effects on cell death, measured by Annexin V and
PI-staining, as well as subG1 populations (Fig. S5e and S6a-
c) whereas three siITGA2s significantly altered G1 and/or
G2/M phases of the cell cycle, in consistency with their
knockdown efficiency on ITGA2 (Fig. S6a-c). Therefore, cell
death was excluded as a major factor driving cell count
differences which are likely to be primarily caused by cell
cycle arrest. These data demonstrate that ITGA2 promotes
cell cycle which is required for proliferation and self-
renewal of TNBC.
ITGA2 siRNAs inhibit tumor cell migration and
invasion
We subsequently investigated the functions of ITGA2/CD49b
in regulating metastasis-related phenotypes, such as migra-
tion and invasion in multiple human and mouse TNBC cell
lines. Collagen I is one of the primary ligands of integrins,
which can bind extracellularly through the MIDAS motif and
activate the integrin signaling cascade.39 To assess the
impact of CD49b suppression on Collagen I binding, migration
and invasion assays were conducted on collagen I-coated
dishes. Transfection of a smart pool of four siITGA2s
miR-206 in MDA-MB-231 cells, evaluated by flow cytometry. (D) Predicted binding sites between the complementary sequences of
ITGA2 3’UTR (WT) and miR-206. The bottom line shows the mutated C to T (U, in red) within the interaction site of 3’UTR. (E) 3’UTR
luciferase assay shows direct regulation of ITGA2 by miR-206, nZ 3, **t-test PZ 0.005. (F-G) Images (F) and quantified counts (G) of
breast cancer cell-derived mammospheres upon siITGA2 knockdown. **t-test P < 0.01. Error bars represent S.D. values. Scale
bars Z 25 mm (H-I) siITGA2 transfection depletes CD49b protein expression, measured by immunoblotting (H) and flow cytometry
analyses (I). (J) Immunoblots to detect reduced expression of CD49b, phosphorylated FAK (pFAK), and OCT3/4 levels without
affecting total FAK levels upon ITGA2 KD or miR-206 upregulation. (K) Left panel: Flow histogram of CD49b expression in control and
siITGA2-transfected cells and gated sorting of CD49bþþ and CD49blow/- populations, respectively. Right panel: Bioluminescent im-
ages of CD49bþþ and CD49blow/- implants of 100e1000 cells from day 1e10 (D1-D10). (L) Left panel: Fold change of tumor burden
(total photons) to Day 1 (D1) from D1-D20. ** t-test PZ 0.007 on D20. Error bars represent S.D. values. Right panel: Weight of tumors
derived from CD49bþþ and CD49b/low cells, orthotopically implanted at 100e1000 cells (t-test **P Z 0.008).
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significantly suppressed migration of MDA-MB-231 cells
(Fig. 4AeC). In addition, the siRNAs that conveyed the most
effective reduction of CD49 levels as measured by flow
cytometry also led to the most dramatic decrease in cell
density and cell migration (Fig. S7a-b). Subsequently, cell
invasion was measured when migrating cells were overlaid
with Matrigel after the wound scratch was made. Upon
ITGA2 siRNA transfection, MDA-MB-231 cells exhibited a
dramatic decrease of invasion along with reduced cell den-
sity over time compared to the controls (Fig. 4DeF). Cell
migration was also inhibited in mouse TNBC 4T1 cells when
transfected with siRNAs targeting mouse Itga2 (Fig. 4GeI).
Supporting the potential for CD49b serving as a new
therapeutic target to block cancer progression, we further
found that an anti-CD49b neutralizing antibody blocked the
migration of MDA-MB-231 cells during wound healing
(Fig. S7c). Depletion of CD49b specifically abolished the
adhesion of MDA-MB-231 cells to its extracellular matrix
ligand protein Collagen I but had minimal effects on
adhesion to laminin and fibronectin (Fig S7d). However, the
wound-healing migration of these cells was significantly
altered on any of these three substrates upon ITGA2 KD (Fig
S7e), suggesting that the CD49b-mediated tumor cell
motility might be intrinsic and independent of its binding to
extracellular matrix.
ITGA2 knockdown inhibits the expression of genes
in lipid metabolism and cell cycle pathways
To further understand the downstream pathways regulated
by ITGA2 in breast cancer, we performed RNA sequencing to
compare the transcriptomes of ITGA2 KD and control MDA-
MB-231 cells and identified the top 195 differentially
expressed genes, based on a cutoff of FDR <0.05 and Log2
(Fold Change) > 0.48 or < 0.48 (Fig. 5A and Table S1).
Notably, based on Metascape analysis (http://metascape.
org), ITGA2 KD altered the pathways of lipid metabolism,
retinoid metabolism and transport, cell cycle, response to
wounding, regulation of protein kinase activity, and other
pathways, including representative genes such as ACLY,
CCND1, CCND3, MCM5, TGFB2, PCNA, ADAMTS1, MAP3K5
(Fig. 5BeE and S8a-b). ACLY-mediated acetyl-CoA produc-
tion for lipid metabolism was recently shown to promote
tumorigenesis in pancreatic cancer.40 CCND1 appeared in
multiple pathways regulated by ITGA2/CD49b, such as cell
cycle, response to stress (toxic substance), regulation of
protein kinase activity (serine/tyrosine phosphorylations),
cytokine signaling, unfolded protein response, mitotic cell
phase transition, androgen receptor (AR) pathway, and
other pathways (Fig. 5B and S8a-b). Meta-analysis of several
breast cancer gene expression datasets using bc-
GenExMiner further demonstrated a significant positive
correlation of ITGA2 with both CCND1 and ITGB1 levels
(Fig. S8c-d). We chose ACLY and CCND1 for further func-
tional studies to determine their importance in CD49b-
mediated phenotypes in TNBC stemness.
ACLY and cyclin D1 are CD49b targets enhancing
cancer stemness and cell cycling
ACLY was one of the top genes downregulated in ITGA2 KD
cells and we hypothesized that it is a regulator of cancer
stemness in breast cancer. We first confirmed a decreased
protein level of ACLY in siRNA-mediated ITGA2 KD cells as
well as ACLY KD cells (Fig. 6A). Using LC/mass spectrometry
analysis with a labeled standard control, we detected a
reduced concentration of cellular Acetyl-CoA levels upon
ITGA2 KD (Fig. 6B). ACLY KD also mimicked ITGA2 KD in
inhibiting mammosphere formation (Fig. 6C), without
significantly altering total cell counts or cell density in
wound healing (Fig. S9a-b), suggesting a role of ACLY in
stemness regulation independent of cell cycle effects.
We then continued to determine if CD49b-regulated
cell cycle attributes to CCND1. ITGA2 KD also decreased
the protein levels of CCND1-encoded cyclin D1 (Fig. 6D),
which is an important driver of the G1-S phase transition
during the cell cycle.41 Furthermore, enforced expres-
sion of CCND1 rescued the cell cycle defects in ITGA2 KD
cells (Fig. 6E). Small RNA mediated silencing of CCND1
(KD) also mimicked ITGA2 KD in inhibiting the efficiency
of mammosphere formation (Fig. 6F), suggesting cell
cycle-coupled regulation of cancer stemness. To eval-
uate the effects of ACLY and CCND1 in lung colonization,
we continued to inoculate these three groups of cells
(control, ACLY-KD, CCND1-KD) into mice via the tail
vein. The bioluminescence imaging showed that CCND1
KD instead of ACLY KD mimicked the ITGA2 KD in
inhibiting lung colonization (Fig. 6G and H), suggesting
the essential role of CCND1 in enhancing metastasis of
breast cancer.
ITGA2 pathway components are associated with
poor survival of breast cancer patients
Lastly, we examined the pathological and clinical relevance
of ITGA2 targets and upstream miR-206 in breast cancer.
Similar to ITGA2-based KM Plots, CCND1 and ACLY expres-
sion show a similar pattern of correlation with a short RFS in
ER breast cancer patients (Fig. 7A and B), whereas miR-
206 expression indicates an extended RFS in ER breast
cancer (Fig. 7C). High expression levels of ITGA2 are not
only associated with reduced RFS probability in patients
with ER- or the intrinsic basal subtype of breast cancer
(Fig. 7D and S1), but also in patients with all grade 3 breast
cancer patients independent of ER expression (Fig. 7E
and F, and S9c-d). Consistently, the analysis of another
database also demonstrated the correlation of high ITGA2
expression with poor event free survival of the patients
with TNBC (Fig. 7G). Our recent discoveries and other re-
ports demonstrated that circulating tumor cell (CTC) clus-
ters are enriched with cancer stemness and proliferation
compared to single CTCs.15,16,31,42 Notably, shown by single
cell RNA sequencing from the published databases,16,31
both ACLY and CCND1 expression levels are upregulated in
CTC clusters versus single CTCs isolated from patients with
breast cancer and patient-derived xenografts (Fig. 7H),
correlating with their effects on improved self-renewal and
cell cycle progression respectively.
Since FAK has been known to promote CCND1 expres-
sion43 and both ITGA2 KD and miR-206 could inhibit
FAK phosphorylation (Fig. 2J), our data suggest a regula-
tion network that miR-206 inhibits ITGA2/CD49b-medi-
ated signaling cascade through compromised FAK






Figure 3 ITGA2 knockdown inhibits cell cycle. (A-B) Images (A) and cell counts (B) of MDA-MB-231 cells 48 h after transfections
with siITGA2 (ITGA2-KD) or miR-206 mimic. Cell number was measured via hemocytometer counting (B), n Z 12, P Z 0.002 (ITGA2-
KD), and n Z 3, P Z 0.0012 (miR-206) (t-test). Error bars represent S.D. values. (C) Representative flow cytometry analyses of cell
cycle with phases of subG1, G1, S, and G2M using propidium iodide upon ITGA2-KD and miR-206 overexpression in MDA-MB-231 cells.
(D) Quantified percentage of MDA-MB-231 cells in each cell cycle phase as shown in (C) Top panel: siITGA2 mediated ITGA2-KD and
control, n Z 4 biological replicates; P Z 0.03 (G1); P Z 0.004 (G2M) (t-test). Bottom panel: miR-206 overexpression and control,
nZ 3 biological replicates; PZ 0.01 (G1), 0.02 (S), 0.04 (G2M) (t-test). Error bars represent S.D. values. (E) Percentage of MDA-MB-
231 cells in each cell cycle phase upon ITGA2 cDNA-mediated rescue of G1 arrest in miR-206 transfected cells (gated GFPþ cells
with ITGA2 overexpression). P < 0.05 (t-test). NS Z not significantly different. Error bars represent S.D. values. (F) Percentage of
BT20 cells in each cell cycle phase upon ITGA2-KD. P < 0.01 (t-test). Error bars represent S.D. values.
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phosphorylation and cyclin D1 expression as well as
reduced ACLY expression and metastasis-regulating
pathways (Fig. 7I). The miR-206/ITGA2/ACLY-CCND1
signaling cascade is a clinically relevant target for both
biomarker identification and therapeutic development to




Figure 4 ITGA2 knockdown reduces migration and invasion of TNBC cells in the presence of collagen. (A) Images of migratory
MDA-MB-231 cells with human siITGA2 smart pool-mediated knockdown (ITGA2-KD) and siRNA controls (Con), at 0 and 24 h (h)
following scratched wounding. Cells were plated on collagen I-coated plates. (B) Quantification of relative cell density filled by
ITGA2-KD and control cells in wounded areas, n Z 3; P Z 0.0002 (12 h), 0.0001 (24 h) (t-test). Error bars represent S.D. values.
(C) Normalized migration over confluence of MDA-MB-231 cells during wound healing. P < 0.01 (t-test). Error bars represent
S.D. values. (D-E) Images (D) and relative cell density (E) of invasive MDA-MB-231 cells (A2-KD and control) covered by Matrigel,
at 0 and 48 h after scratched wounding. n Z 3, P Z 0.02 (24 h), 0.007 (48 h) (t-test). Error bars represent S.D. values. (F) Flow
cytometry plots of CD49b levels in MDA-MD-231 cells upon ITGA2 KD. (G-H) Images (G) and quantified wound density (H) of
murine 4T1 mammary cancer cells upon Itga2 KD via siItga2, within 12, 22 (24), and 40 h following scratch wounding. *t-test
P < 0.05 (n Z 3). Error bars represent S.D. values. (I) Flow cytometry analyses of reduced murine Cd49b levels upon Itga2 KD in
4T1 cells.
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Discussion
Our findings have identified that ITGA2/CD49b as a direct
target of miR-206 in promoting breast cancer stemness and
metastasis. The surface integrin protein CD49b can be
potentially targeted by neutralizing antibodies and small
molecules, serving as a new therapeutic target for metastatic




Figure 5 ITGA2 downregulation-altered genes and clusters. (A) Heatmap of differentially expressed 195 genes >1.5 fold change
upon ITGA2 KD via siITGA2 (see Table S1), with most being downregulated (top and middle rows of 169 genes) and a small portion of
upregulated genes (bottom rows of 26 genes). (B) Top 20 gene clusters enriched by ITGA2 KD, colored by p-values. The Metascape
gene list analyses were carried out with the ontology sources of KEGG Pathway, GO, Reactome, Canonical Pathways, and CORUM.
(C-E) Heatmap of genes in representative pathways of cell cycle and regulation of protein kinase activity (C), lipid metabolism (D),
and wound healing and cell migration (E), with representative genes CCND1 and ACLY shown in C and D, respectively.
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CD49b signaling and has been identified as a key mediator of
intracellular signaling by integrins.44,45 Our studies have also
identified several other integrins which expression levels are
associated with an unfavorable RFS of breast cancer, such as
cancer stem cell markers CD49f (integrin a6) and integrin
a7.46e48 Both integrins and FAK can play crucial roles in the
maintenance of breast cancer stem cells.38,49 It might be





Figure 6 ACLY and Cyclin D1 are CD49b targets enhancing self-renewal and cell cycle. (A) Immunoblot of downregulated ACLY
proteins in MDA-MB-231 cells transfected with siACLY and siITGA2 in comparison to siRNA control and siOCT4. (B) Reduced cellular
acetyl-coA levels in the ITGA2-knock down MDA-MB-231 cells, as measured by LC/MS (t-test PZ 0.001, n Z 3 biological replicates).
Error bars represent S.D. values. (C) Compromised mammosphere formation in ACLY KD cells, shown representative images (right
panels) and quantified histograms (left panel) (t-test P < 0.05, n Z 3 biological replicates). Error bars represent S.D. values. Scale
bars Z 30 mm. (D) Immunoblot of downregulated cyclin D1 proteins in MDA-MB-231 cells transfected with siITGA2 compared to
control. (E) siITGA2-induced G1 arrest and altered G2/M phase were rescued by CCND1 overexpression in MDA-MB-231 cells.
*P < 0.05, **P < 0.01 (t-test), n Z 3 biological replicates. Error bars represent S.D. values. (F) Representative images (top panels)
and qualification (bottom panel) of mammosphere formation of MDA-MB-231 cancer cells upon siITGA2 mediated KD. ** t-test
P < 0.01, n Z 3 biological replicates. Error bars represent S.D. values. Scale bars Z 50 mm. (G) Bioluminescence images of
siControl, siACLY, siCCND1-transfected MDA-MB-231 tumor cells upon tail vein infusion (n Z 4 mice each group). (H) Fold change of
lung metastasis signals (total photons, p/s), normalized to day 0 (D0). t-test P Z 0.003 (**), 2e-5 (****), and 7e-5 (****), for D1, D2,
and D3 comparisons between the control and siCCND1 groups, respectively. Error bars represent S.D. values.
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transcription factorOCT3/4with theFAKsignalingpathway to
regulate the breast cancer stemness phenotype.49 As FAK is a
known mediator of the downstream signaling of many integ-
rins incell cycle regulation,50wespeculate thatFAKactivation
may be involved in CD49b signaling-enhanced transactivation
of CCND1 in TNBC. However, the transcriptional regulation of
ACLY has not been well studied and the connection with FAK




Figure 7 ITGA2 pathway is associated with outcomes of the patients with breast cancer. (A-C) Breast Cancer KaplaneMeier Plotter
analyses of RFS correlated with CCND1 expression (a, Log rank P Z 0.043, n Z 701), and ACLY expression (b, Log rank P Z 0.001,
nZ 407), and OS associated withmiR-206 expression (c, Log rank PZ 0.002, nZ 159) in ER-breast cancer with best cut off. (D-F) KM
plots of RFS correlation with ITGA2 expression in ER- (Log rank pZ 0.0406, nZ 189) (D), grade 3 ER- (Log rank PZ 0.048, nZ 347) (E),
and all grade 3 (Log rank P Z 0.037, n Z 444) (F) breast cancer, with best cut off selected in Breast Cancer KaplaneMeier Plotter
analyses. (G) Breast cancer miner plot of any-event (AE) free survival association with ITGA2 expression in TNBC. Log rank PZ 0.02,
nZ 1258, median cut off. (H) Box plot for differential ACLYand CCND1 expression levels between clustered and single CTCs of breast
cancer patients and PDXs (GSE109761 and GSE111065).16,31 Wilcox t test P Z 0.004 and 0.024 for ACLY and CCND1 comparisons,
respectively. (I) Schematic CD49b signaling pathway induced by extracellular matrix factors such as collagen I fibers that result in the
phosphorylation of FAK and upregulation of CCND1 and ACLY levels to promote proliferation, stemness, and metastasis of TNBC.
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CD49b appears to activate cell cycling of breast cancer
stem and progenitor cells in cancer progression. Our global
transcriptome analyses reveal that CD49b regulates cell
cycle, wound healing, and protein kinase pathways related
to self-renewal and migration. CCND1 is amplified and
overexpressed in one of the high risk of relapse subgroup
-Integrative Cluster 2 of ER negative breast cancer with a
very poor prognosis.51 Cell cycle progression through G1
phase in mammalian cells is precisely regulated by integrin-
mediated adhesion to the extracellular matrix growth and
growth factor binding to receptor tyrosine kinases
(RTKs).52,53 These two classes of receptors coordinately
promoteactivationof theG1phase cyclin-dependent kinases
(CDKs), such as CDK4/6, and increase expression of G1 phase
cyclins, especially Cyclin D1/Cyclin E, which then mediate S
phase entry. Our results show that transient ITGA2 knock-
down inhibited TNBC proliferation by inducing G1 arrest.
Previous studies have shown that the adaptor Shc might be
involved in integrin a5 ligation and activation of mitogen-
activated protein kinase (MAPK) activity.54,55 Elucidation of
the molecular mechanisms underlying the upregulation of
CCND1 is clinically relevant, and new targeting strategies
might be useful to strengthen and broaden the application of
the CDK4/6 inhibitors for treatment of metastatic hormone
receptor positive breast cancer in the clinic.56
Altered metabolism has been connected to cellular
reprograming. In addition to cell cycle and stemness-
related pathways, our studies have also discovered that
there are multiple metabolic pathways that are impacted
by ITGA2, such as ACLY-involved lipid metabolism with
acetyl CoA as a notable component. ACLY has recently been
revealed to positively promote tumorigenesis and cell
plasticity via elevated acetyl-CoA abundance and global
histone acetylation.57 Moreover, recent findings show a
contribution of de novo fatty acid synthesis (in which ACLY
is involved) in intestinal tumorigenesis of adenomatous
polyposis coli (APC) mutant mice.58 Our studies confirm a
modulation of ACLY expression by CD49b signaling pathway
and a role of ACLY in breast cancer self-renewal, showing
an unprecedented connection of integrin signaling to ACLY-
mediated lipid metabolism and cancer stemness. Lastly, it
will be important to determine if this is specific to CD49b or
shared with other integrin subunits.
In addition to the tumor autonomous role of CD49 in
promoting cancer stemness, its expression in immune cells
especially in regulatory T cells (Treg)25 needs to be taken
into consideration when it serves as a potential cancer
target. Future studies with conditional Itga2 knockout in
mammary epithelial cells and immune cells respectively
will assist clarifying the extent of impact of Itga2 on tumor
cells versus stromal cells in the metastatic process.
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